Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval for the Promus PREMIER Everolimus-Eluting Platinum Chromium Coronary Stent System ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE